Transmitted HIV drug resistance in treatment‐naive Romanian patients
暂无分享,去创建一个
S. Ruță | S. Mehta | L. Ene | L. Manolescu | D. Duiculescu | A. Temereanca
[1] G. Magiorkinis,et al. Molecular typing of the recently expanding subtype B HIV-1 epidemic in Romania: Evidence for local spread among MSMs in Bucharest area , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[2] P. Narciso,et al. Ultra‐deep sequencing reveals hidden HIV‐1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption , 2012, Journal of medical virology.
[3] A. De Luca,et al. High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype. , 2012, The Journal of antimicrobial chemotherapy.
[4] F. Wit,et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.
[5] Á. Holguín,et al. Increase of Transmitted Drug Resistance among HIV-Infected Sub-Saharan Africans Residing in Spain in Contrast to the Native Population , 2011, PloS one.
[6] A. Hatzakis,et al. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[7] J. Vingerhoets,et al. Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine , 2011, Journal of acquired immune deficiency syndromes.
[8] M. Leal,et al. Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010 , 2011, Virology Journal.
[9] M. Poljak,et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. , 2011, AIDS reviews.
[10] D. Pillay,et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load , 2010, AIDS.
[11] R. Swanstrom,et al. A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. , 2010, The Journal of infectious diseases.
[12] W. Heneine,et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.
[13] M. Poljak,et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. , 2009, The Journal of infectious diseases.
[14] N. Taveira,et al. Antiretroviral Drug Resistance Surveillance among Treatment-Naive Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance , 2009, Antimicrobial Agents and Chemotherapy.
[15] A. Vicente,et al. Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates , 2009, Retrovirology.
[16] C. Delaugerre,et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France , 2009, AIDS.
[17] Anne-Mieke Vandamme,et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.
[18] Christopher H Woelk,et al. A public health model for the molecular surveillance of HIV transmission in San Diego, California , 2009, AIDS.
[19] D. Pillay,et al. O112 Trends in transmitted HIV drug resistance among non-B subtypes in the UK , 2008 .
[20] Robert W Shafer,et al. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. , 2008, AIDS reviews.
[21] Edward P Acosta,et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.
[22] Mark Myatt,et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.
[23] L. Bacheler,et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. , 2007, Journal of virological methods.
[24] D. Richman,et al. Update of the drug resistance mutations in HIV-1: 2007. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[25] John P. Walsh,et al. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom , 2007, AIDS.
[26] D. Otelea,et al. Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[27] C. Pilcher,et al. Diagnosis and management of acute HIV infection. , 2007, Infectious disease clinics of North America.
[28] R. Shafer,et al. Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.
[29] Ingrid A. Beck,et al. Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency , 2006, Journal of Clinical Microbiology.
[30] L. Stuyver,et al. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[31] Klaus Korn,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.
[32] V. Calvez,et al. Clinically Relevant Genotype Interpretation of Resistance to Didanosine , 2005, Antimicrobial Agents and Chemotherapy.
[33] Matthew J. Gonzales,et al. Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.
[34] M. Peeters,et al. Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected With Non-B HIV-1 Variants and Matched Patients Infected With HIV-1 Subtype B , 2004, Journal of acquired immune deficiency syndromes.
[35] S. Hetherington,et al. Antiviral Efficacy of Abacavir in Antiretroviral Therapy-Experienced Adults Harbouring HIV-1 with Specific Patterns of Resistance to Nucleoside Reverse Transcriptase Inhibitors , 2004, Antiviral therapy.
[36] Maureen M Goodenow,et al. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. , 2003, Biochemistry.
[37] Colombe Chappey,et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.
[38] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[39] J. Kahn,et al. Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.
[40] Diana D. Huang,et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. , 2002, AIDS research and human retroviruses.
[41] S. Hammer,et al. The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.
[42] J. Fantini,et al. Mutation Patterns of the Reverse Transcriptase and Protease Genes in Human Immunodeficiency Virus Type 1-Infected Patients Undergoing Combination Therapy: Survey of 787 Sequences , 1999, Journal of Clinical Microbiology.
[43] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[44] D. Richman,et al. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. , 1998, AIDS Research and Human Retroviruses.
[45] T. Merigan,et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy , 1996, Journal of virology.
[46] E. Arnold,et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[47] S. Ruță,et al. The serologic significance of F viral genotype for human immunodeficiency virus type 1 epidemic. , 1994, The Journal of infectious diseases.
[48] J. Durham. THE CHANGING HIV/AIDS EPIDEMIC , 1994, Nursing Clinics of North America.
[49] M Slatkin,et al. A cladistic measure of gene flow inferred from the phylogenies of alleles. , 1989, Genetics.
[50] K. Mandaliya,et al. Drug-resistant HIV-1 in sub-Saharan Africa: clinical and public health studies , 2013 .
[51] M. Soares,et al. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[52] S. Ruță,et al. Dynamics of the HIV-1 variability in adults from Bucharest, 1992-1998. , 1999, Romanian journal of virology.
[53] R. Hudson,et al. A statistical test for detecting geographic subdivision. , 1992, Molecular biology and evolution.
[54] S. Hammer,et al. Antiretroviral Drug Resistance Testing in Adult Hiv-1 Infection: 2008 Recommendations of an International Aids Society–usa Panel , 2022 .